Collaborations & Alliances

Daiichi Sankyo, Glycotope Enter Strategic ADC Alliance

To develop ADC combining Daiichi's ADC technology with Glycotope's investigational TA-MUC1 antibody

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Daiichi Sankyo Co., Ltd. and Glycotope GmbH have signed an option agreement for future strategic collaboration and licensing to develop an antibody drug conjugate (ADC) by combining Daiichi’s ADC technology with Glycotope’s investigational tumor-associated TA-MUC1 antibody PankoMab-GEX. Once a feasibility study has been successfully completed, Daiichi has the right to exercise its option for worldwide exclusive rights to develop and commercialize PankoMab-GEX ADC. If exercised, G...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters